University of Tasmania and Parkinson's Research Foundation bridge gap in Parkinson's knowledge with first of its kind resourceFree online course ...

A gold-standard University College of London study found a type of weight-loss jab had no benefit in alleviating a condition ...

Discover how groundbreaking brain stimulation technology is giving hope to individuals with paralysis Learn about the ...

Christa Miller, who plays Liz, recently confirmed on Instagram that filming for Shrinking Season 3 kicks off next week in ...

MintNeuro will lead the custom development and integration of low-power, function-specific integrated circuits and systems ...

The study may suggest that other researchers should be less optimistic about the prospects for treating a range of other ...

The GLP-1 drug, exenatide, has no positive impact on the movement, symptoms or brain imaging of people with Parkinson's, ...

Treatment with exenatide, a GLP-1 receptor agonist, was comparable to placebo in slowing the rate of Parkinson’s disease ...

Americans will soon have access to an infusion device that provides round-the-clock effective relief of Parkinson's disease.

The FDA on Tuesday signed off on Supernus Pharmaceuticals’ apomorphine hydrochloride injection—to be marketed under the brand ...

The GLP-1 drug, exenatide, has no positive impact on the movement, symptoms or brain imaging of people with Parkinson's, finds a new study led by UCL researchers.